We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

A Cost-effectiveness Analysis of Prevaccination Testing for Hepatitis B in Adolescents and Preadolescents

Tao Sheng C. Kwan-Gett, MD; Robert C. Whitaker, MD, MPH; Kathi J. Kemper, MD, MPH
Arch Pediatr Adolesc Med. 1994;148(9):915-920. doi:10.1001/archpedi.1994.02170090029003.
Text Size: A A A
Published online


Objective:  To study the clinical effectiveness and cost-effectiveness of prevaccination testing for hepatitis B virus in adolescents and preadolescents.

Design:  Decision analysis model comparing (1) prevaccination testing for hepatitis B surface antibodies, (2) no testing, and (3) testing at the same time as the first vaccine dose. Sensitivity analyses of the first two strategies were performed varying the seroprevalence of hepatitis B surface antibodies, compliance with follow-up, and costs of testing.

Setting:  Charges for testing and vaccination were obtained from Children's Hospital and Medical Center in Seattle, Wash. Vaccination compliance, hepatitis B surface antibodies seroprevalence, and vaccine response rates are from published literature.

Patients:  A hypothetical cohort of 100 000 11-year-old children presenting for well-child care.

Main Outcome Measures:  Rate of complete vaccination, cost of testing and vaccination for each cohort, and cost per patient protected from hepatitis B virus.

Results:  No testing was the most cost-effective strategy. Prevaccination testing elevated costs by $2.9 million for every 100 000 patients and lowered the rate of complete vaccination by 22% compared with vaccination without testing. For prevaccination testing to be cost-effective, the seroprevalence of hepatitis B surface antibodies needed to be greater than 40%. As the seroprevalence of hepatitis B surface antibodies decreased, the ratio of testing costs to vaccination costs had to decrease for prevaccination testing to remain cost-effective. Even with perfect compliance, prevaccination testing required high seroprevalence rates to be cost-effective.

Conclusions:  For most populations of preadolescents and adolescents, prevaccination testing for hepatitis B virus is not effective in terms of cost or rate of complete vaccination.(Arch Pediatr Adolesc Med. 1994;148:915-920)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.